ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO – Get Free Report) passed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $57.12 and traded as high as $57.84. ALPS Medical Breakthroughs ETF shares last traded at $57.60, with a volume of 22,302 shares changing hands.
ALPS Medical Breakthroughs ETF Price Performance
The firm has a 50-day moving average price of $58.14 and a two-hundred day moving average price of $57.12.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in SBIO. NTV Asset Management LLC increased its holdings in shares of ALPS Medical Breakthroughs ETF by 1.2% in the third quarter. NTV Asset Management LLC now owns 17,283 shares of the company’s stock valued at $1,008,000 after purchasing an additional 200 shares during the last quarter. Harbor Investment Advisory LLC purchased a new position in ALPS Medical Breakthroughs ETF during the second quarter worth approximately $29,000. Kestra Advisory Services LLC boosted its stake in ALPS Medical Breakthroughs ETF by 27.6% during the first quarter. Kestra Advisory Services LLC now owns 8,186 shares of the company’s stock worth $428,000 after buying an additional 1,772 shares during the last quarter. Sterling Investment Advisors Ltd. boosted its stake in ALPS Medical Breakthroughs ETF by 8.1% during the second quarter. Sterling Investment Advisors Ltd. now owns 23,800 shares of the company’s stock worth $1,539,000 after buying an additional 1,775 shares during the last quarter. Finally, Phoenix Wealth Advisors boosted its stake in ALPS Medical Breakthroughs ETF by 33.6% during the third quarter. Phoenix Wealth Advisors now owns 11,212 shares of the company’s stock worth $654,000 after buying an additional 2,822 shares during the last quarter.
About ALPS Medical Breakthroughs ETF
The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.
Recommended Stories
- Five stocks we like better than ALPS Medical Breakthroughs ETF
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for ALPS Medical Breakthroughs ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALPS Medical Breakthroughs ETF and related companies with MarketBeat.com's FREE daily email newsletter.
